Ricardo Fishman
Jul 10, 2017 · 3 min read

Seed Round Opportunity: $2.4 million | Life Sciences Tools | Biopharmaceutical


$2.4 million Seed Round opportunity in a Company with proprietary (IP) breakthrough technologies in the Life Sciences Tools and Analytics (LST) segment to address material productivity and capital optimization opportunities in the drug discovery and characterization processes by the global Biopharmaceutical industry.

This industry spends $140bn per year in R&D. A significant portion is allocated to new drug discoveries and the identification of viable biosimilars. Notwithstanding these massive investments, less than 12% of all candidates that go through pre-clinical trials obtain approval to become commercial products. Some studies now peg the cost of bringing a new drug to market at around $2.6 billion per approved drug. However, depending on each firm’s success rate in attaining approvals this figure can be as high as $12bn per drug and as low as $3.6bn for some of the leading global players. If costs weren’t enough of a motivation to pursue better and more efficient technologies to aid in pre-clinical phases, long timelines are also prevalent; it takes 10 to 13 years to bring a single new drug through the preclinical R&D phase, clinical trials and obtain regulatory approval. Companies (pharmaceutical, biotech, biosimilars), and academic and government sectors alone, invest between $6 and $9 billion every year on Life Science Tools and technologies to try and improve their drug discovery and characterization processes, improve approval success rates by identifying earlier on in the lifecycle the likelihood of safety and efficacy issues, reduce time to market and costs, and allocate valuable resources to other worthy activities.

The Company has obtained a number of method and device patents for its breakthrough High Throughput Developability and Comparability Assessment technologies, completed proof of concept of its analytical prototype platform at its lab against benchmark proteins, garnished accolades from the FDA, scientific and research communities and is working with its key OEM vendors to optimize and produce a low footprint version of the commercial version of the analytics platform.

At this time, the Company is looking to complete its Seed Capital stage, which already includes $500,000 from individual experts in the field of medicine and regional institutional investors as well as over $1.1 mm from the NSF SBIR program and matching grants. The funds will enable the completion of the seamless data integration between the analytical components of the Company’s platform, as well as the design of the commercial prototype version working in collaboration with the Company’s two strategic OEM vendors. In tandem with these critical milestones the Company will begin on site validation with a Biosimilar CRO and a Global Biopharma at their labs which will set the stage towards the commercialization process; currently, the Company is working with a CRO and with NIST to attain biosimilar protein validation at its lab.

To attain these milestones, the Company is looking to obtain up to $2.4 million in additional Seed Capital. Between 1Q and 2Q 2018, the Company estimates to be in the market raising its Series A, which will enable it to complete the recruitment of the commercial and in-house engineering teams, and begin delivering against confirmed orders for its commercial version of the platform.

For investors domiciled in Puerto Rico, local regulations may provide for income and capital gain tax treatments that could potentially enhance their return on investment.

Qualified accredited investors only are invited to contact us for additional information. Respectfully, we will not reply to Brokers and Intermediaries at this point.

Ricardo Fishman K.

Cel: (787) 221–6404

Ricardofishman@yahoo.com

http://linkedin.com/in/ricardofishman